Transdermal patch peptides

Continuous-delivery peptide patches — the 2026 emerging format

Transdermal patches deliver peptides continuously through the skin's stratum corneum, producing steadier plasma levels than injection and avoiding both gastric degradation and injection burden. The format is still emerging in peptide therapy — most current products are unverified and the bioavailability data is thin — but the 2026 wave of BPC-157 patches and emerging melatonin-peptide combinations represents a real category. This is the index of every peptide we cover that ships in patch form.

1 peptide we cover in this format

Ranked by 30-day query volume

BPC-157
+42%
Pentadecapeptide derived from a human gastric-juice protein, extensively studied in rodent models for tendon, ligament, and gut-tissue healing via angiogenesis and fibroblast-migration mechanisms. Human evidence base remains thin. FDA Interim Category 2 pending July 2026 PCAC review.
RecoveryRecovery pillar48.2K/moCat 2 → reviewWADA prohibited

New to peptides?

Read the medical-reviewer-signed primer that explains how peptide therapy actually works — what the evidence says, what it doesn't, and how to read the regulatory landscape.

Read: What are peptides?